|
12 Sep 2025 |
Dabur
|
Consensus Share Price Target
|
538.85 |
552.36 |
- |
2.51 |
hold
|
|
|
|
|
04 Aug 2023
|
Dabur
|
BOB Capital Markets Ltd.
|
538.85
|
669.00
|
569.70
(-5.42%)
|
|
Buy
|
|
|
Q1 revenue grew 11% YoY aided by strong growth across categories, except beverages that saw the impact of unseasonal rains
|
|
04 Aug 2023
|
Dabur
|
Axis Direct
|
538.85
|
610.00
|
569.70
(-5.42%)
|
Target met |
Buy
|
|
|
Recommendation: With an upside potential of 10% from the CMP, we maintain our BUY rating on the stock.
|
|
03 Aug 2023
|
Dabur
|
ICICI Securities Limited
|
538.85
|
625.00
|
555.05
(-2.92%)
|
Target met |
Accumulate
|
|
|
Dabur reported healthy volume-led (3% YoY) revenue performance (9% YoY – ex Badshah), driven by a sharp recovery in Healthcare business (led by Digestive and OTC) and 11% YoY revenue growth in HPC. We liked the strong volume-driven performance in oral care (8% YoY vs 2.5% category growth) in HPC.
|
|
03 Aug 2023
|
Dabur
|
Prabhudas Lilladhar
|
538.85
|
600.00
|
555.05
(-2.92%)
|
Target met |
Accumulate
|
|
|
|
|
05 May 2023
|
Dabur
|
BOB Capital Markets Ltd.
|
538.85
|
628.00
|
505.00
(6.70%)
|
|
Buy
|
|
|
Broad-based growth across categories in Q4, barring healthcare which is navigating the high Covid base
|
|
05 May 2023
|
Dabur
|
ICICI Securities Limited
|
538.85
|
580.00
|
505.00
(6.70%)
|
Target met |
Accumulate
|
|
|
Below expected. Subdued performance in health care and HPC dragged down overall revenue growth to 6% YoY. This was led by (1) lower primary sales (vs secondary) due to unseasonal rains, and (2) significant downtrading in rural due to persistent slowdown.
|
|
05 May 2023
|
Dabur
|
ICICI Direct
|
538.85
|
675.00
|
505.00
(6.70%)
|
|
Buy
|
|
|
|
|
04 May 2023
|
Dabur
|
Prabhudas Lilladhar
|
538.85
|
590.00
|
530.40
(1.59%)
|
Target met |
Accumulate
|
|
|
|
|
04 May 2023
|
Dabur
|
Sharekhan
|
538.85
|
605.00
|
505.00
(6.70%)
|
|
Buy
|
|
|
|
|
03 Feb 2023
|
Dabur
|
ICICI Securities Limited
|
538.85
|
650.00
|
554.45
(-2.81%)
|
|
Buy
|
|
|
Dabur’s revenue print (+3% YoY India, +9.5% on 3-year CAGR basis) was impacted due to (1) Healthcare segment lapping on a high base of covid, (2) downtrading in rural and late onset of winter impacting HPC segment
|